Communiqués Allakos Inc.

Actions

ALLK

US01671P1003

Temps réel estimé Cboe BZX Autres places de cotation 19:13:13 07/06/2024			Varia. 5j.	Varia. 1 janv.
1,125 ^USD	-2,17 %		-10,00 %	-58,79 %

28/05	Allakos Inc. annonce le dosage du premier patient dans l'essai de phase 1 de l'AK006 dans l'urticaire chronique spontanée	CI
09/05	Allakos Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Allakos Announces First Patient Dosed in Phase 1 Trial of AK006 in Chronic Spontaneous Urticaria	28/05	GL
Allakos Provides Business Update and Reports First Quarter 2024 Financial Results	09/05	GL
Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results	14/03	GL
Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results	14/03	AQ
Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024	26/02	GL
Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024	26/02	AQ
Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition	12/02	GL
Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition	12/02	AQ
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Allakos Inc. - ALLK	08/02	PR
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Allakos Inc. - ALLK	31/01	PR
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Allakos Inc. - ALLK	23/01	PR
Allakos Announces a Restructuring to Focus on Development of AK006	16/01	GL
Allakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Did Not Meet Their Primary Endpoints	16/01	GL
Allakos Announces a Restructuring to Focus on Development of AK006	16/01	AQ
Allakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Did Not Meet Their Primary Endpoints	16/01	AQ
Allakos Provides Business Update and Reports Third Quarter 2023 Financial Results	13/11	GL
Allakos Provides Business Update and Reports Third Quarter 2023 Financial Results	13/11	AQ
Allakos Appoints Neil Graham to its Board of Directors	30/08/23	GL
Allakos Provides Business Update and Reports Second Quarter 2023 Financial Results	09/08/23	GL
Allakos Provides Business Update and Reports Second Quarter 2023 Financial Results	09/08/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Allakos Inc.

Actions

ALLK

US01671P1003

Communiqués

Filtres